Skye Bioscience Selects NextPharma As Phase 2 Contract Drug Manufacturer

Skye Bioscience, Inc. (OTCQB: SKYE) , a pharmaceutical company developing a proprietary, cannabinoid derivative to treat glaucoma, has selected NextPharma as its contract manufacturing organization (“CMO”) for its Phase 2 clinical trial material.

“As is typical with pharmaceutical drug production, early and late stage production of clinical trial materials are usually undertaken by CMOs with different skill sets. Skye completed an extensive search and due diligence process to choose an ideal CMO to produce SBI-100 Ophthalmic Emulsion for its next stages of development and we are pleased that NextPharma has partnered with us on this project,” stated Punit Dhillon, CEO and chair of Skye. “Apart from their broad expertise in manufacturing commercially-approved drugs for major pharmaceutical clients, NextPharma is also experienced in handling controlled substances, which will be valuable in serving Skye’s needs.”

“During our pre-Investigational New Drug (“IND”) meeting with the FDA’s Division of Ophthalmology, we confirmed that our nonclinical safety package would be …

Full story available on Benzinga.com

Skye Bioscience Selects NextPharma As Phase 2 Contract Drug Manufacturer on Benzinga